Summary
Agilent Technologies, Inc. reported solid performance in its fiscal year ended October 31, 2019. The company, a global leader in life sciences, diagnostics, and applied chemical markets, saw a 5% increase in net revenue to $5.163 billion, driven by growth in its Diagnostics and Genomics and Agilent CrossLab segments, which both increased by 8%. The Life Sciences and Applied Markets segment experienced a more modest 1% revenue increase. Acquisitions played a significant role in the company's growth, with the notable acquisitions of ACEA Biosciences and BioTek contributing positively to results, particularly in the cell analysis and life science instrumentation markets. Financially, Agilent demonstrated strong operational execution. While net income was significantly impacted by discrete tax benefits in 2019 ($1.071 billion) and a tax charge in 2018, the underlying operational performance was robust. The company continued its commitment to shareholder returns through share repurchases, buying back approximately $723 million of its stock under its new repurchase program, and by declaring dividends. Agilent maintains a healthy balance sheet with $1.382 billion in cash and cash equivalents, supporting its ongoing investments in R&D and strategic acquisitions.
Financial Highlights
56 data points| Revenue | $5.16B |
| Cost of Revenue | $2.36B |
| Gross Profit | $2.81B |
| R&D Expenses | $404.00M |
| SG&A Expenses | $1.46B |
| Operating Expenses | $4.22B |
| Operating Income | $941.00M |
| Interest Expense | $74.00M |
| Net Income | $1.07B |
| EPS (Basic) | $3.41 |
| EPS (Diluted) | $3.37 |
| Shares Outstanding (Basic) | 314.00M |
| Shares Outstanding (Diluted) | 318.00M |
Key Highlights
- 1Agilent Technologies reported a 5% year-over-year increase in net revenue, reaching $5.163 billion for the fiscal year ended October 31, 2019.
- 2The Diagnostics and Genomics segment and the Agilent CrossLab segment both achieved 8% revenue growth, indicating strong demand in these areas.
- 3Acquisitions, notably BioTek and ACEA Biosciences, contributed to revenue growth and expanded Agilent's presence in key markets like cell analysis and life science instrumentation.
- 4The company maintained a solid financial position with $1.382 billion in cash and cash equivalents as of October 31, 2019.
- 5Agilent actively returned capital to shareholders through significant share repurchases totaling $723 million during the year and consistent dividend payments.
- 6Operating expenses, including R&D and SG&A, saw increases, partly due to integration costs from acquisitions and increased wages, but overall operating margin remained stable.
- 7The company is focused on differentiating its product solutions, enhancing customer experience, and achieving continued earnings growth in the upcoming fiscal year.